How to Get Addyi in Wyoming: Telehealth, Prescriptions, and Pharmacies

What Is Addyi and Why Does It Require a Special Prescription Process?

Flibanserin (Addyi) is the only FDA-approved non-hormonal oral treatment for acquired, generalized HSDD in premenopausal women. The FDA granted approval in August 2015 following two adequate and well-controlled trials, including the BEGONIA trial, which enrolled 1,378 women and demonstrated statistically significant improvements in the number of satisfying sexual events and in sexual desire scores versus placebo over 24 weeks [1]. A pooled analysis of three key phase-3 trials (N=2,400) found that women on flibanserin 100 mg nightly reported a mean increase of 0.5 satisfying sexual events per month above placebo, alongside meaningful reductions in distress scores [2].

Because flibanserin carries a risk of severe hypotension and syncope when combined with alcohol or moderate-to-strong CYP3A4 inhibitors, the FDA imposed a Risk Evaluation and Mitigation Strategy (REMS) at approval [3]. The REMS requires that every prescriber and dispensing pharmacy complete a brief certification, and that patients receive a Medication Guide and counseling about alcohol avoidance before the first prescription is dispensed. This does not mean a woman in Wyoming must visit a physical clinic. It means her telehealth provider must be REMS-certified and document the required counseling in the visit note.

The FDA label states: "Because of the risk of severe hypotension and syncope, Addyi is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Addyi REMS Program" [3]. Once the prescriber and pharmacy are certified, the prescription process mirrors any other controlled medication workflow.

Telehealth Prescribing of Addyi in Wyoming: What the Law Allows

Wyoming permits telehealth prescribing of flibanserin for new patients without a prior in-person visit. The Wyoming Medical Practice Act and the state's telehealth statutes allow a prescriber-patient relationship to be established via synchronous audio-video consultation, provided the clinician holds an active Wyoming license or a valid Interstate Medical Licensure Compact (IMLC) credential.

Because Addyi is not a controlled substance under the federal Controlled Substances Act, it does not trigger the Ryan Haight Act's in-person visit requirement that applies to Schedule II-V drugs [4]. A Wyoming-licensed NP, PA, or physician can therefore conduct a telehealth intake visit, gather the required HSDD history, review medications and alcohol use, complete REMS counseling, and transmit an electronic prescription to a REMS-certified pharmacy, all in a single 20- to 30-minute visit.

The American College of Obstetricians and Gynecologists notes that telehealth modalities "can increase access to care for patients in rural and underserved areas," a consideration that applies directly to Wyoming's largely rural population [5]. Wyoming has fewer than 580,000 residents spread across 97,000 square miles, making telehealth the practical route for most women seeking HSDD treatment.

Clinicians at HealthRX who prescribe flibanserin complete REMS certification and document the alcohol-interaction counseling for every patient, satisfying the FDA requirement before the prescription is sent [3].

Step-by-Step: How to Get an Addyi Prescription in Wyoming

Getting flibanserin in Wyoming involves four concrete steps: clinical evaluation, REMS counseling, pharmacy selection, and delivery.

Step 1. Book a telehealth visit. Schedule a synchronous video or phone visit with a Wyoming-licensed prescriber who is REMS-certified for Addyi. Visits typically run 20 to 30 minutes. Bring a list of all current medications, including over-the-counter drugs and supplements, because CYP3A4 inhibitors (fluconazole, clarithromycin, grapefruit products) are contraindicated with flibanserin [3].

Step 2. Complete the HSDD evaluation. The prescriber will use validated screening tools, most commonly the Female Sexual Distress Scale-Revised (FSDS-R) and the Female Sexual Function Index (FSFI), to confirm the HSDD diagnosis. Scores on the FSDS-R of 11 or higher support clinically significant distress [6]. The visit note will document symptom duration, onset pattern, absence of a substance or medical cause, and absence of relationship factors as the sole driver.

Step 3. Receive REMS counseling and sign the patient acknowledgment. Before the prescription is sent to the pharmacy, the prescriber provides the FDA Medication Guide and documents alcohol-avoidance counseling [3]. The patient acknowledgment form is retained in the medical record.

Step 4. Prescription sent to a REMS-certified pharmacy. The prescriber transmits the e-prescription to a certified pharmacy. Most mail-order REMS pharmacies ship to Wyoming addresses. Standard delivery runs 3 to 7 business days. Expedited shipping cuts that to 1 to 2 business days for an added fee.

What Labs Are Needed Before Starting Addyi in Wyoming?

Flibanserin has no mandatory pre-treatment laboratory panel specified in the FDA label [3]. Prescribers do not need TSH, estradiol, or liver function tests to issue the prescription. This differs from hormonal therapies like testosterone or estradiol, which require baseline serum levels.

Clinically, most providers order a targeted panel to rule out comorbid causes of low libido. A thyroid-stimulating hormone (TSH) test screens for hypothyroidism, which mimics HSDD and affects roughly 5% of the U.S. adult female population [7]. A basic metabolic panel helps flag hepatic impairment, since moderate or severe hepatic impairment is an absolute contraindication to flibanserin due to increased drug exposure [3]. The FDA label states that flibanserin "is contraindicated in patients with hepatic impairment" and that alcohol use combined with the drug "can cause severe hypotension and syncope" [3].

A complete medication reconciliation is more important than any blood draw. The prescriber must confirm no concurrent use of strong CYP3A4 inhibitors. If a patient is on fluconazole, she must stop it and wait at least two days before starting flibanserin [3]. If she is on a moderate CYP3A4 inhibitor, the prescriber should weigh the combined risk of hypotension before proceeding.

Baseline blood pressure is worth documenting because hypotension is dose-limiting. Women with resting systolic pressure below 90 mmHg are poor candidates [3].

Who Can Prescribe Addyi in Wyoming?

Any licensed prescriber in Wyoming with REMS certification can write for flibanserin. That includes physicians (MD or DO), nurse practitioners (APRN-CNP), and physician assistants (PA-C). Wyoming grants full prescriptive authority to APRNs who hold a controlled substance registration, and PAs operate under a written practice agreement with a supervising physician [8].

The practical implication: women in Wyoming are not limited to OB/GYN or urology specialists. A primary care NP or a telehealth PA with REMS certification can evaluate, diagnose, and prescribe. The REMS program certification takes roughly 30 minutes online and is available at the Addyi REMS website.

For telehealth specifically, the prescriber must hold an active Wyoming license or a compact license through the IMLC, Nurse Licensure Compact (NLC), or PA Licensure Compact. Multi-state compact licensure has made it straightforward for large telehealth platforms to staff Wyoming prescribers without requiring full individual state licensure applications.

Addyi Pharmacy Options in Wyoming: Retail, Mail-Order, and 503A Compounding

Wyoming residents have three dispensing channels for flibanserin.

Retail and specialty pharmacies. National chains (Walgreens, CVS, Walmart Pharmacy) are REMS-certified in many Wyoming locations. The prescriber should confirm the specific branch is certified before sending the e-prescription, as certification is at the individual pharmacy unit level, not the chain level [3]. A quick call to the pharmacy's REMS coordinator confirms status in under two minutes.

REMS-certified mail-order pharmacies. Mail-order is the most common route for Wyoming patients given driving distances. Certified mail-order pharmacies ship to all Wyoming ZIP codes. Addyi 100 mg lists at approximately $99 per month with the Sprout Pharmaceuticals savings card for eligible commercially insured patients. Patients without commercial insurance may qualify for the Addyi patient assistance program, which Sprout administers directly [3].

503A compounding pharmacies. Wyoming permits 503A compounding pharmacies to prepare and dispense flibanserin to individual patients with a valid, patient-specific prescription [9]. A 503A pharmacy compounds for named patients, not for general stock. This channel may reduce out-of-pocket cost for patients with documented hypersensitivity to excipients in the commercial tablet. The pharmacist must still comply with REMS dispensing requirements, including providing the FDA Medication Guide [3]. The FDA's 503A compounding framework requires that compounded versions not be essentially a copy of a commercially available product without clinical justification [9].

Wyoming Medicaid does not cover Addyi for HSDD. Private insurance coverage varies widely. In a 2017 analysis published in the Journal of Sexual Medicine, fewer than 30% of commercial insurance plans covered flibanserin without prior authorization, and the average co-pay for those that did cover it exceeded $30 per month [10].

Prior Authorization for Addyi in Wyoming: What Documentation You Need

If a Wyoming insurer requires prior authorization (PA), the prescriber typically submits four categories of documentation.

First, the clinical diagnosis of HSDD confirmed by validated scale scores (FSDS-R score of 11 or higher, or FSFI total score of 26.55 or below are common thresholds cited in the literature) [6]. Second, documentation that the low desire is not fully explained by a concurrent medical condition or medication. Third, evidence that the patient has been counseled on REMS requirements. Fourth, a statement that no contraindicated medications are co-prescribed.

Some Wyoming plans add a step-therapy requirement, asking that the patient have tried and failed a course of psychotherapy or counseling for sexual dysfunction. The International Society for the Study of Women's Sexual Health (ISSWSH) 2019 guidelines state that pharmacotherapy and psychotherapy can be offered concurrently rather than sequentially [11]. Citing the ISSWSH position in the PA letter often resolves step-therapy denials.

Response time for PA decisions in Wyoming under state law is generally 3 business days for standard review and 1 business day for urgent review. If a PA is denied, the patient has appeal rights under Wyoming Insurance Code § 26-40-108.

How Long Until You Receive Addyi in Wyoming?

The timeline from consultation to medication in hand breaks into three segments.

The prescriber visit takes 20 to 30 minutes and can be booked same-day or next-day on most telehealth platforms. Prescription verification and REMS pharmacy processing adds 1 business day in most cases. Shipping to Wyoming via standard mail adds 2 to 5 business days, with rural ZIP codes in Sublette or Fremont County occasionally running one day longer than urban Cheyenne or Casper addresses.

Total elapsed time for a patient without prior authorization requirements: 3 to 7 business days. With prior authorization: add 3 to 10 business days for insurer review. Patients who qualify for the Sprout direct-pay savings card can bypass insurance processing entirely and shorten the timeline to the lower end of that range.

Can You Transfer an Addyi Prescription to Wyoming?

Yes. A valid flibanserin prescription issued in any U.S. state can be transferred to a REMS-certified pharmacy in Wyoming, provided the prescription has remaining refills and has not expired. Wyoming follows standard NABP transfer rules: a prescription may be transferred once between pharmacies for drugs that are not controlled substances, or transferred multiple times if both the sending and receiving pharmacies use a real-time electronic database [12].

The key practical point: if a patient relocates to Wyoming and her existing flibanserin prescription was issued by an out-of-state prescriber who is not licensed in Wyoming, the prescription can be transferred to a Wyoming pharmacy and dispensed for the remaining refills. When refills are exhausted, she will need a new prescription from a Wyoming-licensed provider. Telehealth makes that renewal straightforward.

REMS certification does not transfer with the prescription. The receiving Wyoming pharmacy must independently hold REMS certification before it can dispense flibanserin.

Alcohol, Drug Interactions, and Safety Monitoring While on Addyi

The alcohol interaction is the most clinically consequential safety concern for women using flibanserin in Wyoming. The FDA REMS program was originally structured to require a blood-alcohol level at dispensing, a requirement that was later modified to counseling-only following a 2015 reassessment [3]. The current requirement is documented counseling, not an alcohol test.

Two clinical pharmacology studies sponsored by Sprout Pharmaceuticals found that 0.4 g/kg alcohol (approximately two standard drinks) with a single 100 mg flibanserin dose produced a mean maximum systolic blood pressure drop of 28 mmHg, with hypotension or syncope events in 4 of 25 participants [3]. The FDA label states: "Women who drink alcohol should be thoroughly counseled about the risk and the importance of not drinking alcohol within two hours of taking Addyi or before going to sleep" [3].

CYP3A4 inhibitors are the second major interaction class. Oral contraceptives containing ethinyl estradiol are moderate CYP3A4 inhibitors that may increase flibanserin exposure; the label advises caution rather than contraindication [3]. A patient on a combined oral contraceptive should be told she may experience more pronounced sedation or hypotension and should start flibanserin at bedtime with adequate time to sleep before any next-day obligations.

SSRIs and SNRIs are commonly co-prescribed in women seeking HSDD treatment, since depression and sexual dysfunction overlap. Flibanserin is not a serotonin reuptake inhibitor, but it acts as a 5-HT1A agonist and 5-HT2A antagonist. The label does not list SSRIs as contraindicated, but the prescriber should document the rationale for concurrent use and monitor for CNS depression [3].

Follow-up visits are recommended at 8 weeks. If no meaningful improvement in satisfying sexual events or distress scores is documented by 8 weeks, the FDA label advises discontinuation [3].

What to Expect From Addyi: Realistic Outcomes

Flibanserin produces modest but statistically significant improvements in HSDD. The BEGONIA trial reported a mean increase of 0.8 satisfying sexual events per month over 24 weeks for flibanserin versus 0.5 for placebo, a net treatment effect of approximately 0.3 events per month [1]. A pooled phase-3 analysis (N=2,400) found that women in the flibanserin group scored meaningfully lower on the FSDS-R distress subscale compared to placebo at week 24, with a mean difference of approximately 0.6 points on a 0-to-4 scale [2].

Discontinuation rates due to adverse events in clinical trials ran at 13% for flibanserin versus 6% for placebo, primarily driven by somnolence (11%), dizziness (11%), and nausea (10%) [3]. Most adverse events peaked in the first two to four weeks and attenuated with continued use.

Patients should be counseled that flibanserin is not an on-demand drug. It requires nightly dosing and takes four to eight weeks for meaningful effect. Women who stop taking it because they notice no change at two weeks are leaving before the therapeutic window fully opens.

The ISSWSH 2019 consensus recommends shared decision-making that includes discussion of the drug's modest effect size, the alcohol restriction, and the availability of non-pharmacological alternatives such as mindfulness-based sex therapy, before a final prescribing decision is made [11].